Search research articles
Contact Us
Filters
Showing results (101-110 of 459) with videos related to
Page
of 46
Sort By:
Expert Review of Anticancer Therapy
|
June 2, 2020
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions
Maddalena Donini, Sebastiano Buti, Francesco Massari, et al.
Clinical Genitourinary Cancer
|
February 23, 2023
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis
Fernando Sabino Marques Monteiro, Andrey Soares, Alessandro Rizzo, et al.
Diagnostics (Basel, Switzerland)
|
February 12, 2021
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors
Matteo Giulietti, Monia Cecati, Berina Sabanovic, et al.
Oncology Research
|
January 8, 2026
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review
Giacomo Iovane, Luca Traman, Michele Maffezzoli, et al.
Expert Review of Molecular Diagnostics
|
March 11, 2025
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean?
Matteo Rosellini, Elisa Tassinari, Linda Danielli, et al.
Biomed Research International
|
October 5, 2013
Progress of molecular targeted therapies for advanced renal cell carcinoma
Alessandro Conti, Matteo Santoni, Consuelo Amantini, et al.
Advances in Urology
|
July 20, 2012
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder
Matteo Santoni, Francesco Catanzariti, Daniele Minardi, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
April 29, 2022
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
Alessandro Rizzo, Veronica Mollica, Sara Merler, et al.
Immunotherapy
|
March 26, 2025
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis
Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, et al.
Analytical and Quantitative Cytopathology and Histopathology
|
June 16, 2015
Role of the pathologist in active surveillance for prostate cancer
Roberta Mazzucchelli, Andrea B Galosi, Matteo Santoni, et al.
Page
of 46
Search research articles
Search
Showing results (101-110 of 459) with videos related to
Sort By:
Page
of 46
Expert Review of Anticancer Therapy
|
June 2, 2020
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions
Maddalena Donini, Sebastiano Buti, Francesco Massari, et al.
Clinical Genitourinary Cancer
|
February 23, 2023
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis
Fernando Sabino Marques Monteiro, Andrey Soares, Alessandro Rizzo, et al.
Diagnostics (Basel, Switzerland)
|
February 12, 2021
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors
Matteo Giulietti, Monia Cecati, Berina Sabanovic, et al.
Oncology Research
|
January 8, 2026
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review
Giacomo Iovane, Luca Traman, Michele Maffezzoli, et al.
Expert Review of Molecular Diagnostics
|
March 11, 2025
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean?
Matteo Rosellini, Elisa Tassinari, Linda Danielli, et al.
Biomed Research International
|
October 5, 2013
Progress of molecular targeted therapies for advanced renal cell carcinoma
Alessandro Conti, Matteo Santoni, Consuelo Amantini, et al.
Advances in Urology
|
July 20, 2012
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder
Matteo Santoni, Francesco Catanzariti, Daniele Minardi, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
April 29, 2022
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
Alessandro Rizzo, Veronica Mollica, Sara Merler, et al.
Immunotherapy
|
March 26, 2025
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis
Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, et al.
Analytical and Quantitative Cytopathology and Histopathology
|
June 16, 2015
Role of the pathologist in active surveillance for prostate cancer
Roberta Mazzucchelli, Andrea B Galosi, Matteo Santoni, et al.
Page
of 46